Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target Lowered to $199.00 at JPMorgan Chase & Co.

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price objective lowered by JPMorgan Chase & Co. from $204.00 to $199.00 in a research report released on Monday morning,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the specialty pharmaceutical company’s stock.

Several other research firms have also recently commented on JAZZ. Truist Financial raised their target price on shares of Jazz Pharmaceuticals from $200.00 to $205.00 and gave the company a “buy” rating in a research note on Thursday, August 28th. The Goldman Sachs Group raised their target price on shares of Jazz Pharmaceuticals from $162.00 to $185.00 and gave the company a “buy” rating in a research note on Friday, August 29th. Morgan Stanley set a $183.00 target price on shares of Jazz Pharmaceuticals in a research note on Friday. Zacks Research raised shares of Jazz Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Friday, August 15th. Finally, Wells Fargo & Company set a $170.00 price objective on shares of Jazz Pharmaceuticals in a research note on Wednesday, October 22nd. Fourteen analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $179.33.

Jazz Pharmaceuticals Stock Up 0.6%

Jazz Pharmaceuticals stock opened at $139.33 on Monday. The stock has a market cap of $8.45 billion, a price-to-earnings ratio of -20.70, a PEG ratio of 8.23 and a beta of 0.28. The company has a current ratio of 1.62, a quick ratio of 1.37 and a debt-to-equity ratio of 1.17. The company’s 50-day moving average price is $130.88 and its two-hundred day moving average price is $117.25. Jazz Pharmaceuticals has a 52 week low of $95.49 and a 52 week high of $148.06.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) EPS for the quarter, missing the consensus estimate of ($5.61) by ($2.64). The company had revenue of $1.05 billion for the quarter, compared to analyst estimates of $1.05 billion. Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The firm’s quarterly revenue was up 2.1% on a year-over-year basis. During the same period in the previous year, the business posted $5.30 EPS. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. On average, analysts expect that Jazz Pharmaceuticals will post 16.96 EPS for the current fiscal year.

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, Director Bruce C. Cozadd sold 6,000 shares of the firm’s stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $128.62, for a total value of $771,720.00. Following the completion of the transaction, the director directly owned 429,973 shares in the company, valued at $55,303,127.26. This trade represents a 1.38% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders have sold 11,500 shares of company stock valued at $1,525,280 in the last ninety days. Company insiders own 4.30% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Quent Capital LLC acquired a new position in shares of Jazz Pharmaceuticals in the third quarter worth about $44,000. Forum Financial Management LP boosted its holdings in shares of Jazz Pharmaceuticals by 8.5% in the third quarter. Forum Financial Management LP now owns 2,603 shares of the specialty pharmaceutical company’s stock worth $343,000 after buying an additional 203 shares during the period. Philip James Wealth Mangement LLC boosted its holdings in shares of Jazz Pharmaceuticals by 1.5% in the third quarter. Philip James Wealth Mangement LLC now owns 16,032 shares of the specialty pharmaceutical company’s stock worth $2,113,000 after buying an additional 235 shares during the period. Cardinal Capital Management boosted its holdings in shares of Jazz Pharmaceuticals by 3.4% in the third quarter. Cardinal Capital Management now owns 14,472 shares of the specialty pharmaceutical company’s stock worth $1,907,000 after buying an additional 475 shares during the period. Finally, Lecap Asset Management Ltd. acquired a new position in shares of Jazz Pharmaceuticals in the third quarter worth about $833,000. 89.14% of the stock is currently owned by institutional investors and hedge funds.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.